Harvard Bioscience, Inc. (HBIO) is making moves to slim down and speed up. The company announced Friday it's reshaping its manufacturing footprint in a bid to cut costs and streamline production, and investors seemed to like what they heard.

Shuttering Massachusetts, Going National and International

Here's the plan: Harvard Bioscience is closing its Holliston, Massachusetts plant. Domestic manufacturing will consolidate at the company's Minneapolis, Minnesota hub, while some production heads overseas to facilities in Germany, Sweden, and the United Kingdom.

CEO John Duke framed the reorganization as building on flexibility gained from recent refinancing. The idea is to consolidate key operations and leverage scale and expertise that's already sitting across their various sites.

The math here is pretty straightforward. Management projects roughly $3 million in savings during 2027, ramping up to about $4 million in annual savings once everything's fully implemented beginning in 2028. Those gains come from lower overhead, trimming the SKU count, and making better use of existing assets.

Managing the Transition

The company is reconfiguring roles throughout its operations and working through a phased transition plan. Leadership emphasized they're focused on maintaining order fulfillment and product quality while everything shifts around.

The Holliston facility isn't closing overnight—it'll stay operational through 2026 to keep supporting customers. Harvard Bioscience expects to wrap up the entire consolidation by the first quarter of 2027.

Of course, nothing comes free. Transition-related costs will likely push expenses higher into mid-2027.

HBIO Price Action: Shares were up 0.63% at $0.54 during premarket trading on Friday. The stock has dropped over 69% in the past year.